Human Papillomavirus Vaccines: Who Should Get Them and Why?

  • Stéphane Paulus
  • Simon Dobson
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 609)

In 2006, the first of two vaccines for human papillomavirus (HPV) prevention was approved for use in several countries. This has prompted great attention to be paid to HPV infections and their consequences. As the genital HPV types are acquired sexually, acceptability to the public of a vaccine to prevent a sexually transmitted infection (STI) will be an important issue in ensuring good uptake of the vaccine by those who would most benefit.


Cervical Cancer Sexually Transmitted Infection Genital Wart Recurrent Respiratory Papillomatosis Recurrent Respiratory Papillomatosis Patient 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Block SL, Nolan T, Sattler C, Barr E, Giacoletti KED, and Marchant CD, et al. (2006). Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. Pediatrics, 118:2135–2145.PubMedCrossRefGoogle Scholar
  2. Bosch FX and de Sanjosé. (2003). Chapter 1: human papillomavirus and cervical cancer–burden and assessment of causality. J Natl Cancer Inst Monographs, 31:3–13.PubMedGoogle Scholar
  3. Clifford G, Franceschi S, Diaz M, Munoz N, and Villa LL. (2006). Chapter 3: HPV type-distribution in women with and without cervical neoplastic diseases. Vaccine, 24(S3):26–34.CrossRefGoogle Scholar
  4. Cogliano V, Grosse y, Baan R, Straif K, Secretan B, and El Ghissassi F. (2005). Carcinogenicity of combined oestrogen–progestagen contraceptives and menopausal treatment. Lancet Oncol, 6:552–553.PubMedCrossRefGoogle Scholar
  5. Davis K, Dickman ED, Ferris D, and Dias JK. (2004) Human papillomavirus vaccine acceptability among parents of 10- to 15-year-old adolescents. J Low Genit Tract Dis, 8:188–194.PubMedCrossRefGoogle Scholar
  6. Dobson S, Deeks S, and Money D. (2007). National advisory committee on immunization (NACI) statement on human papillomavirus vaccine. Can Commun Dis Rep, 33:1–32.Google Scholar
  7. Dubin G for the HPV Vaccine Adolescent Study Investigators, GlaxoSmithKline Biologicals, Rixensart, Belgium. (2005) Enhanced immunogenicity of a candidate human papillomavirus (HPV) 16/18 L1 virus-like particle vaccine (VLP) with novel ASO4 adjuvant in pre-teens/adolescents. Abstract No: 4042. Poster presented at ICAAC 2005.Google Scholar
  8. Harper DM, Franco EL, Wheeler C, Ferris DG, Jenkins D, and Schuind A et al. (2004). Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomized controlled trial. Lancet, 364:1757–1765.PubMedCrossRefGoogle Scholar
  9. Harper DM, Franco EL, Wheeler C, Moscicki A, Romanowski B, and Roteli-Martins CM et al. (2006). Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomized control trial. Lancet, 367:1247–1255.PubMedCrossRefGoogle Scholar
  10. Herrero R, Hildesheim A, Bratti C et al. (2000). Population-based study of human papillomavirus infection and cervical neoplasia in rural Costa Rica. J Natl Cancer Inst, 92:464–474.PubMedCrossRefGoogle Scholar
  11. Kahn JA, Zimet GD, Bernstein DI, Riedesel JM, Lan D, Huang B, and Rosenthal S. (2005). Pediatricians’ intention to administer human papillomavirus vaccine: the role of practice characteristics, knowledge, and attitudes. J Adolesc Health, 37:502–510.PubMedCrossRefGoogle Scholar
  12. Kitchener HC, Castle PE, and Cox JT. (2006). Chapter 7: achievements and limitations of cervical cytology screening. Vaccine, 24(S3):63–70.CrossRefGoogle Scholar
  13. Lacey CJN, Lowndes CM, and Shah KV. (2006). Chapter 4: burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease. Vaccine, 24(S3):35–41.CrossRefGoogle Scholar
  14. Moscicki AB, Schiffman M, Kjaer S, and Villa LL. (2006). Chapter 5: updating the natural history of HPV and anogenital cancer. Vaccine, 24(S3):42–51.CrossRefGoogle Scholar
  15. Munoz N, Castellsague X, Berrington de Gonzalez A, and Gissmann L. (2006). Chapter 1: HPV in the etiology of human cancer. Vaccine, 24(S3):1–10.CrossRefGoogle Scholar
  16. Riedesel JM, Rosenthal SL, Zimet GD, Bernstein DI, Huang B, Lan D, And Kahn JA. (2005). Attitudes about human papillomavirus vaccine among family physicians. J Pediatr Adolesc Gynecol, 18:391–398.PubMedCrossRefGoogle Scholar
  17. Sellors JW, Mahony JB, and Kaczorowski J, et al. (2000). Prevalence and predictors of human papillomavirus infection in women in Ontario, Canada. CMAJ, 163:503–508.PubMedGoogle Scholar
  18. Sellors JW, Karwalajtys TL, Kaczorowski J, Mahoney JB, Lytwyn A, Chong S, Sparrow J, Lorincz A. (2002). Prevalance of carcinogenic human papillomavirus (HPV) infection in older women. CMAJ, 167:871–873.PubMedGoogle Scholar
  19. Shykhon M, Kuo M, and Pearman K. (2002). Recurrent respiratory papillomatosis. Clin Otolaryngol, 27:237–243.PubMedCrossRefGoogle Scholar
  20. Stanley M. (2006). Immune responses to human papillomavirus. Vaccine, 24(S1):16–22.CrossRefGoogle Scholar
  21. Stanley M, Lowy DR, and Frazer I. (2006). Chapter 12: prophylactic HPV vaccines: underlying mechanisms. Vaccine, 24S3:106–113.CrossRefGoogle Scholar
  22. Villa LL, Costa RLR, Petta CA, Andrade RP, Ault KA, and Giuliano AR, et al. (2005). Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomized double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol, 6:271–278.PubMedCrossRefGoogle Scholar
  23. Villa LL, Ault KA, Giuliano AR, Costa RLR, Petta CA, and Andrade RP, et al. (2006a). Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18. Vaccine, 24(27–28):5571–5583.PubMedCrossRefGoogle Scholar
  24. Villa LL, Costa RLR, Petta CA, Andrade RP, Paavonen J, and Iversen OE, et al. (2006b). High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 virus-like particle vaccine through 5 years of follow-up. British Journal of Cancer, 95:1459–1466.PubMedCrossRefGoogle Scholar
  25. Winer RL, Lee SK, and Hughes JP et al. (2003). Genital human papillomavirus infection: Incidence and risk factors in a cohort of female university students. Am J Epidemiol, 157: 218–226.PubMedCrossRefGoogle Scholar
  26. World Health Organization. (2005). Preventing Chronic Diseases: A Vital Investment. WHO Global Report, Geneva.Google Scholar

Copyright information

© Springer 2008

Authors and Affiliations

  • Stéphane Paulus
  • Simon Dobson
    • 1
  1. 1.Clinical Associate Professor, Division of Pediatric Infectious Diseases, Department of PediatricsUniversity of British Columbia, BC Children&s HospitalVancouverCanada

Personalised recommendations